Ariad Pharmaceuticals, Inc. (ARIA) Announces Preliminary Safety And Efficacy Data Of Ponatinib In Patients With Newly Diagnosed CML From Discontinued Phase 3 EPIC Trial
6/2/2014 9:34:57 AM
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced preliminary safety and efficacy data from the discontinued Phase 3 EPIC trial of Iclusig® (ponatinib) vs. imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML). These data are being featured this afternoon in a poster presentation and a poster discussion session at the 2014 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois.
Help employers find you! Check out all the jobs and post your resume.
comments powered by